AUS
NZ
UK
CA
USA
IND
Highlights
- Major Acquisition: Telix Pharmaceuticals is acquiring early-stage drug candidates and a proprietary biologics platform from ImaginAb, Inc. for an initial $73 million, with an additional $299 million tied to future milestones.
- Next-Generation Therapies: The acquired assets include promising drug candidates targeting surface-cell proteins such as DLL3 and integrin αvβ6, addressing high-grade neuroendocrine tumors, small-cell lung cancer, and more.
- California Research Facility: As part of the deal, Telix gains access to ImaginAb's state-of-the-art research facility in California, enhancing its R&D capabilities.
Telix Pharmaceuticals Ltd (ASX:TLX) has announced a significant $372 million asset acquisition agreement with antibody engineering company ImaginAb, Inc. The deal will expand Telix's pipeline of next-generation drug candidates and bolster its capabilities in addressing critical unmet needs in oncology and other therapeutic areas.
The agreement includes an upfront payment of $73 million, with a further $299 million contingent upon Telix achieving specific development and commercial milestones. This structure underscores the high potential of the assets, which focus on innovative approaches to cancer therapy.
Next-Generation Drug Candidates
The acquired assets include a portfolio of early-stage drug candidates targeting surface-cell proteins such as DLL3, which is highly expressed in high-grade neuroendocrine tumors and small-cell lung cancer, and integrin αvβ6, a protein associated with cancer and wound healing.
These drug candidates leverage small-engineered antibody formats, offering precise cancer targeting, rapid tumor uptake, and efficient blood clearance. These features align with Telix's commitment to developing advanced, targeted therapies that improve patient outcomes.
R&D Boost with California Facility
In addition to the drug candidates, Telix will take ownership of ImaginAb’s cutting-edge research facility in California and a proprietary biologics technology platform. This acquisition enhances Telix’s research and development capabilities, positioning the company to accelerate its pipeline progress and diversify its therapeutic focus areas.
